Drug
Bms 986489
Bms 986489: highest development phase Phase 3, developed by Bristol-Myers Squibb. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Bristol-Myers Squibb
Trials
| Drug | Phase | Indication |
|---|---|---|
| BMS-986489 (Atigotatug+Nivolumab) NCT06646276 | Phase 3 | Extensive-Stage Small Cell Lung Cancer |
Latest
No recent events.
Follow Bms 986489 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.